Eyepoint Pharmaceuticals Inc

Healthcare · Biotechnology

3.30$ +0.6% vs. previous close Closing price · As of: Oct 2, 2026

Statements

Balance Sheet

Eyepoint Pharmaceuticals Inc (EYPT) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Total Assets" came in at 228 million USD. Tick rows to compare them in a chart.

Income Statement Balance Sheet Cash Flow Ratios

Annual Quarterly

Amounts Change % Common size %

Last 12 Full history

Download as CSV

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Balance Sheet EYPT
Line item	Q3 16	Q4 16	Q1 17	Q2 17	Q3 17	Q4 17	Q1 18	Q2 18	Q3 18	Q4 18	Q1 19	Q2 19	Q3 19	Q4 19	Q1 20	Q2 20	Q3 20	Q4 20	Q1 21	Q2 21	Q3 21	Q4 21	Q1 22	Q2 22	Q3 22	Q4 22	Q1 23	Q2 23	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26
Total Assets	25	20	18	19	13	14	50	72	89	78	82	91	79	73	80	70	77	92	187	179	168	263	245	233	220	180	155	176	160	355	329	324	301	418	363	301	252	364	288	228
Current Assets	24	19	16	18	13	14	18	40	58	48	48	59	47	42	50	40	48	63	159	152	142	238	220	206	192	173	146	167	150	345	318	295	269	383	327	265	216	329	250	189
Cash	14	12	13	17	12	13	16	39	56	45	43	44	32	22	26	23	29	45	139	128	120	179	102	82	75	96	106	140	133	281	271	91	80	100	85	71	75	102	78	110
Cash & Short-Term Investments	23	18	15	17	12	13	16	39	56	45	43	44	32	22	26	23	29	45	139	128	120	212	191	171	157	145	122	143	136	331	299	280	254	371	318	256	204	306	223	180
Receivables	0.5	0.5	0.3	0.3	0.3	0.3	0.5	0.4	0.5	0.6	2.3	9.6	8.9	11	14	7.4	9.4	9.5	12	15	14	18	20	23	21	16	10	11	0.5	0.8	3.0	1.4	0.4	0.6	0.4	0.6	1.0	0.7	1.2	0.1
Inventory	-0.5	-0.5	-0.3	-0.3	0.0	-0.3	0.0	-0.4	-0.5	0.3	0.9	1.7	2.6	2.1	3.4	3.8	3.6	5.3	5.6	5.4	4.6	3.6	3.3	3.3	3.5	2.9	4.1	4.3	4.6	3.9	4.3	3.7	2.8	2.3	2.1	2.7	2.1	1.8	1.3	1.9
Property, Plant & Equipment	0.3	0.2	0.2	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.4	0.4	0.4	0.4	0.4	0.4	0.5	0.6	0.6	2.9	2.4	2.3	0.5	4.8	1.0	1.4	2.6	2.9	–	–	–	–	–	–	–	–	–	–	–	–
Goodwill	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Intangible Assets	0.9	0.7	0.5	0.4	0.2	0.4	32	31	31	30	30	29	28	28	27	26	26	25	25	24	23	23	22	22	21	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Total Liabilities	10	5.0	5.0	5.3	4.3	4.3	42	60	41	41	62	63	63	65	64	65	69	73	71	72	76	79	78	82	84	84	76	118	101	89	79	96	82	82	64	55	52	58	58	62
Current Liabilities	4.8	4.9	4.9	5.3	4.3	4.3	21	22	22	21	25	11	10	12	10	9.6	13	15	13	16	20	24	32	33	34	35	27	69	64	63	63	62	49	49	42	33	30	37	37	42
Short-Term Debt	–	–	–	–	–	–	13	17	–	–	0.8	0.4	0.5	0.5	4.6	0.6	6.8	8.4	5.9	9.1	11	0.8	10	10	11	11	5.3	1.0	1.1	0.6	1.1	1.1	1.3	1.2	1.8	–	2.0	2.0	2.1	2.6
Accounts Payable	1.0	1.1	0.7	1.0	1.8	1.5	2.8	6.7	4.1	2.6	6.3	6.1	5.5	4.2	5.2	3.9	5.2	4.8	5.9	5.4	6.6	7.4	7.3	7.1	6.1	5.9	9.5	11	9.6	6.5	7.1	14	7.3	12	16	20	10	10	19	17
Long-Term Debt	0.0	0.0	0.0	0.0	0.0	0.0	13	17	17	18	32	46	47	47	48	50	51	38	38	36	36	37	29	29	29	29	29	–	–	–	–	–	–	–	–	–	–	–	–	–
Shareholders' Equity	14	15	13	13	9.0	9.9	8.2	12	48	38	20	28	16	8.3	16	4.2	7.6	19	116	107	93	184	167	151	136	96	78	57	59	266	250	228	219	337	298	246	200	306	230	166
Retained Earnings	-299	-299	-305	-311	-317	-323	-330	-364	-397	-408	-428	-439	-455	-465	-478	-491	-495	-511	-523	-533	-550	-569	-590	-609	-628	-671	-693	-715	-728	-742	-771	-802	-832	-873	-918	-978	-1,037	-1,105	-1,190	-1,284
Shares Outstanding	3.4	3.4	3.4	3.9	3.9	4.5	4.6	5.5	7.5	9.5	9.5	11	11	11	12	12	13	15	25	29	29	33	37	37	37	37	37	38	38	42	53	53	54	65	70	70	70	83	86	87

Showing the most recent 40 periods — older statements are on file for this stock.

Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?

Balance Sheet

Cookie settings